Overlevelsesraten efter 12 måneder var 98, 6% for Advagraf, 95, 7% for Prograf og 97, 6% for ciclosporin; i Advagrafgruppen døde 3 patienter (alle mænd), i Prografgruppen døde 10 patienter (3 kvinder, 7 mænd), og i ciclosporingruppen døde 6 patienter (3 kvinder, 3 mænd).
The 12-month patient survival rates were 98.6% for Advagraf, 95.7% for Prograf and 97.6% for ciclosporin; in the Advagraf arm 3 patients died (all male), in the Prograf arm 10 patients died (3 female, 7 male) and in the ciclosporin arm 6 patients died (3 female, 3 male).